See more conditions. Neuromyelitis Optica Mayo Clinic is recognized as a center of excellence for neuromyelitis optica diagnosis, treatment and research. Advertising Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Federal Government. Read our disclaimer for details. Last Update Posted : August 12, Study Description. Detailed Description:. Drug Information available for: Cetirizine Cetirizine hydrochloride.
FDA Resources. Arms and Interventions. Outcome Measures. Immunological measures related to eosinophil activity. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: 18 years to 85 Meet criteria for the diagnosis of neuromyelitis optica as outlined by Wingerchuk et al in Alternatively patients may be included if they have had an episode of myelitis or optic neuritis in combination with a positive NMO IgG antibody, as positive antibody with a first episode is highly associated with future relapse.
Disease duration of at least 6 months Stable, without any NMO relapses, for the 3 months prior to the baseline assessment visit Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information PHI in accordance with national and local subject privacy regulations.
Exclusion Criteria: Current therapy with daily cetirizine or another daily antihistamine for any indication Known hypersensitivity to cetirizine, hydroxyzine, or any component of the formulation Change in NMO disease-modifying therapy in the 3 months prior to baseline assessment Pregnancy or planning pregnancy during the study period Severe renal or hepatic impairment Inability to complete the study protocol for any reason.
The aim is to establish a repository consisting of clinical information, radiological data, serum, peripheral blood lymphocytes, plasma, cerebrospinal fluid CSF , and tissue specimens collected prospectively from patients with CNS diseases and controls. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised. A single copy of these materials may be reprinted for noncommercial personal use only. See more conditions. The median treatment duration with satralizumab in the double-blind period was Multiple imputation for censored data resulted in hazard ratios ranging from 0.
The between-group difference in the change in the mean VAS pain score was 4. The rates of serious adverse events and infections did not differ between groups.
0コメント